drugset
Drugs / metopimazine
last change Jan 2026 re-read 2 minutes ago

metopimazine

also known as NG101 · EXP 999 · Metopimazina

Gene therapy (AAV / viral vector)

Developed for
age-related macular degeneration · idiopathic gastroparesis · spinal cord injury
Investigated by
Neurogastrx, Inc. · Elisigen, Inc. · ORA, Inc.

Trials 3 · a red edge is where a trial was stopped

today NCT06500429 · Ph 2 NCT05984927 · Ph 1/2 NCT04303195 · Ph 2
202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/21 trial
Phase 1/2 NCT05984927 Sep 2023 → Jan 2026 overdue age-related macular degeneration Elisigen, Inc. Active not recruiting No outcome recorded
Phase 22 trials
Phase 2 NCT06500429 Jun → Sep 2024 — Neurogastrx, Inc. Completed No outcome recorded
Phase 2 NCT04303195 Aug 2020 → Feb 2023 idiopathic gastroparesis Neurogastrx, Inc. Completed No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT03935321 Comparator May 2019 → Feb 2023 spinal cord injury University of Zurich Completed No outcome recorded

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 7 sources stand behind the page.

FieldValueCited text
Known as metopimazine “The aim of this study is to assess the safety and efficacy of oral NG101, the mesylate salt of metopimazine, for the treatment of gastroparesis.” PMID 40367443 ↗ May 2025
Known as EXP 999 ChEMBL registry synonym — accepted as the source's own label CHEMBL398615 ↗
Known as Metopimazina ChEMBL registry synonym — accepted as the source's own label CHEMBL398615 ↗
Known as NG101 “NG101, a recombinant human antibody, neutralises the neurite growth-inhibiting protein Nogo-A, promoting neural repair and motor recovery in animal models of spinal cord injury.” PMID 39706632 ↗ Jan 2025
4

NCT05984927 ↗

NCT06500429 ↗

NCT04303195 ↗

NCT03935321 ↗
Action Inhibit “NG101, a recombinant human antibody, neutralises the neurite growth-inhibiting protein Nogo-A” PMID 39706632 ↗ Jan 2025
Modality Gene therapy (AAV / viral vector) “NG101 AAV gene therapy” NCT05984927 ↗
Route Intrathecal “Six intrathecal injections were administered every 5 days over 4 weeks” PMID 39706632 ↗ Jan 2025